JP2006526624A5 - - Google Patents

Download PDF

Info

Publication number
JP2006526624A5
JP2006526624A5 JP2006509816A JP2006509816A JP2006526624A5 JP 2006526624 A5 JP2006526624 A5 JP 2006526624A5 JP 2006509816 A JP2006509816 A JP 2006509816A JP 2006509816 A JP2006509816 A JP 2006509816A JP 2006526624 A5 JP2006526624 A5 JP 2006526624A5
Authority
JP
Japan
Prior art keywords
dispersion
container
nanoparticles
aerosol
propellant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006509816A
Other languages
English (en)
Other versions
JP4680894B2 (ja
JP2006526624A (ja
Filing date
Publication date
Priority claimed from US10/449,443 external-priority patent/US7459146B2/en
Application filed filed Critical
Publication of JP2006526624A publication Critical patent/JP2006526624A/ja
Publication of JP2006526624A5 publication Critical patent/JP2006526624A5/ja
Application granted granted Critical
Publication of JP4680894B2 publication Critical patent/JP4680894B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Claims (4)

  1. 薬を含んでなる分散した固相、および
    噴霧剤および賦形剤ナノ粒子を含んでなる連続液相
    を含み、前記ナノ粒子が１００ｎｍ未満の平均粒子直径を有する、安定した医薬品分散体。
  2. 計量バルブを有する煙霧剤容器、および
    容器内に配置された請求項１に記載の安定した医薬品分散体
    を含んでなる定量吸入器。
  3. 煙霧剤容器を提供するステップと、
    前記容器に請求項１に記載の医薬品分散体を装填するステップと、
    を含んでなる、煙霧剤分散体を製造する方法。
  4. 薬を含んでなる分散した固相と、噴霧剤を含んでなる連続液相とを含んでなる分散体に、有効量のナノ粒子を添加するステップを含んでなる、医薬品分散体を安定化する方法。
JP2006509816A 2003-05-30 2004-04-08 安定化させた煙霧剤分散体 Expired - Fee Related JP4680894B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/449,443 US7459146B2 (en) 2003-05-30 2003-05-30 Stabilized aerosol dispersions
PCT/US2004/010847 WO2004108118A1 (en) 2003-05-30 2004-04-08 Stabilized aerosol dispersions

Publications (3)

Publication Number Publication Date
JP2006526624A JP2006526624A (ja) 2006-11-24
JP2006526624A5 true JP2006526624A5 (ja) 2007-05-24
JP4680894B2 JP4680894B2 (ja) 2011-05-11

Family

ID=33451787

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006509816A Expired - Fee Related JP4680894B2 (ja) 2003-05-30 2004-04-08 安定化させた煙霧剤分散体

Country Status (6)

Country Link
US (1) US7459146B2 (ja)
EP (1) EP1628645A1 (ja)
JP (1) JP4680894B2 (ja)
KR (1) KR20060038938A (ja)
CN (1) CN1798549B (ja)
WO (1) WO2004108118A1 (ja)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060257324A1 (en) * 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
US7459146B2 (en) * 2003-05-30 2008-12-02 3M Innovative Properties Company Stabilized aerosol dispersions
US20040242729A1 (en) * 2003-05-30 2004-12-02 3M Innovative Properties Company Stabilized particle dispersions containing surface-modified inorganic nanoparticles
US7109247B2 (en) * 2003-05-30 2006-09-19 3M Innovative Properties Company Stabilized particle dispersions containing nanoparticles
DE102004053310A1 (de) * 2004-11-04 2006-05-11 Wacker Chemie Ag Mikrowellenaktive Siliconelastomere
EP1700825A1 (de) * 2004-12-23 2006-09-13 Degussa AG Oberflächenmodifizierte, strukturmodifizierte Titandioxide
US8062670B2 (en) * 2005-08-05 2011-11-22 3M Innovative Properties Company Compositions exhibiting improved flowability
US8367734B1 (en) 2005-08-11 2013-02-05 Amphastar Pharmaceuticals Inc. Stable epinephrine suspension formulation with high inhalation delivery efficiency
US20070292688A1 (en) * 2005-08-18 2007-12-20 Eastman Kodak Company Silylamine modified nanoparticulate carriers
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
US7767736B2 (en) * 2005-12-05 2010-08-03 3M Innovative Properties Company Flame retardant polymer composition
DE102006000691A1 (de) * 2006-01-02 2007-07-05 Henkel Kgaa Aerosol-Reiniger mit korrosionsinhibierender Wirkung
US20100119697A1 (en) * 2006-05-10 2010-05-13 3M Innovative Properties Company Compositions and coatings containing fluorescent, inorganic nanoparticles
CN101108166B (zh) * 2006-07-19 2011-07-27 鲁明华 定量纳米气雾剂及其制备方法
WO2008087909A1 (ja) * 2007-01-16 2008-07-24 Sumitomo Bakelite Company, Ltd. 医療用粒子、及び分析用粒子、並びにそれらの製造方法
DE102007008663A1 (de) * 2007-02-20 2008-08-21 Merck Patent Gmbh Bindemittel
EP2137533A2 (en) * 2007-04-19 2009-12-30 3M Innovative Properties Company Uses of water-dispersible silica nanoparticles for attaching biomolecules
US8597959B2 (en) * 2007-04-19 2013-12-03 3M Innovative Properties Company Methods of use of solid support material for binding biomolecules
JP5349838B2 (ja) * 2007-11-30 2013-11-20 和光純薬工業株式会社 ｓｍａｌｌＲＮＡの取得用担体、取得方法及び取得用試薬
EP2291460A2 (en) * 2008-05-08 2011-03-09 3M Innovative Properties Company Surface-modified nanoparticles
KR100961280B1 (ko) 2008-05-21 2010-06-03 한국생명공학연구원 형광특성이 향상된 풀러렌-실리카 나노입자, 이의 제조방법및 이의 용도
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
AU2010299607B2 (en) 2009-09-25 2016-07-28 Tonix Medicines, Inc. Formulations comprising triptan compounds
CN102416179B (zh) 2010-09-28 2014-05-07 益得生物科技股份有限公司 用于哮喘的吸入性复方组合物
CA2819635A1 (en) 2010-12-01 2012-06-07 Spinal Modulation, Inc. Directed delivery of agents to neural anatomy
EP3319907B1 (de) 2015-07-10 2020-08-05 Evonik Operations GmbH Sio2 enthaltende dispersion mit hoher salzstabilität
WO2017009032A1 (de) 2015-07-10 2017-01-19 Evonik Degussa Gmbh Metalloxid enthaltende dispersion mit hoher salzstabilität
US10723628B2 (en) 2015-07-10 2020-07-28 Evonik Operations Gmbh SiO2 containing dispersion with high salt stability
US10767103B2 (en) 2015-10-26 2020-09-08 Evonik Operations Gmbh Method of obtaining mineral oil using a silica fluid
MX2021000908A (es) 2018-07-23 2021-06-08 Trevi Therapeutics Inc Tratamiento de la tos cronica, la dificultad respiratoria y la disnea.
WO2024137511A1 (en) * 2022-12-20 2024-06-27 The Regents Of The University Of Michigan High density microarrays and uses thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE837243C (de) 1944-09-30 1952-04-21 Bayer Ag Schwebemittel fuer waessrige Suspensionen
US2801185A (en) 1952-05-16 1957-07-30 Du Pont Silica hydrosol powder
DE1467023A1 (de) 1964-02-28 1969-01-23 Degussa Verfahren zur Inkorporierung von Wasser in feinst verteilter Kieselsaeure
US4680173A (en) 1977-04-28 1987-07-14 Norman D. Burger Aerosol dispensing system
US4478876A (en) 1980-12-18 1984-10-23 General Electric Company Process of coating a substrate with an abrasion resistant ultraviolet curable composition
US4455205A (en) 1981-06-01 1984-06-19 General Electric Company UV Curable polysiloxane from colloidal silica, methacryloyl silane, diacrylate, resorcinol monobenzoate and photoinitiator
US4491508A (en) 1981-06-01 1985-01-01 General Electric Company Method of preparing curable coating composition from alcohol, colloidal silica, silylacrylate and multiacrylate monomer
US4486504A (en) 1982-03-19 1984-12-04 General Electric Company Solventless, ultraviolet radiation-curable silicone coating compositions
US4522958A (en) 1983-09-06 1985-06-11 Ppg Industries, Inc. High-solids coating composition for improved rheology control containing chemically modified inorganic microparticles
DE3333639A1 (de) 1983-09-17 1985-03-28 Dynamit Nobel Ag Zubereitung von nitroestern fuer die koronartherapie
US5766573A (en) 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5439670A (en) 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
US5037579A (en) 1990-02-12 1991-08-06 Nalco Chemical Company Hydrothermal process for producing zirconia sol
US5258225A (en) 1990-02-16 1993-11-02 General Electric Company Acrylic coated thermoplastic substrate
FR2666962B1 (fr) 1990-09-26 1996-06-14 Oreal Composition antifongique sous forme de spray sec.
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5182097A (en) 1991-02-14 1993-01-26 Virginia Commonwealth University Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
FR2677544B1 (fr) 1991-06-14 1993-09-24 Oreal Composition cosmetique contenant un melange de nanopigments d'oxydes metalliques et de pigments melaniques.
DE4120760A1 (de) * 1991-06-24 1993-03-04 3 M Medica Gmbh Traegersysteme fuer arzneimittel
ATE171865T1 (de) 1991-12-12 1998-10-15 Glaxo Group Ltd Arzneimittel
AU663906B2 (en) 1991-12-12 1995-10-26 Glaxo Group Limited Medicaments
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
FR2698002B1 (fr) 1992-11-13 1995-01-13 Oreal Composition cosmétique de maquillage contenant un fullerène ou un mélange de fullerènes comme agent pigmentant.
IL108416A (en) * 1993-01-25 1998-10-30 Sonus Pharma Inc Colloids with phase difference as contrast ultrasound agents
US5492688A (en) 1993-04-28 1996-02-20 The Center For Innovative Technology Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent
ATE233544T1 (de) 1993-12-02 2003-03-15 Abbott Lab Aerosole als darreichungsform mit cfc-freiem treibmittel
US5508023A (en) 1994-04-11 1996-04-16 The Center For Innovative Technology Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant
IT1275955B1 (it) 1995-03-22 1997-10-24 Dompe Spa Formulazioni farmaceutiche in forma di gel tissotropico
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
FR2746302B1 (fr) 1996-03-20 1998-12-24 Oreal Compositions cosmetiques comprenant des nanopigments
US6054488A (en) 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
FR2759582A1 (fr) 1997-02-14 1998-08-21 Oreal Composition deodorante
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
DE19811790A1 (de) 1998-03-18 1999-09-23 Bayer Ag Nanopartikel enthaltende transparente Lackbindemittel mit verbesserter Verkratzungsbeständigkeit, ein Verfahren zur Herstellung sowie deren Verwendung
FR2781373B1 (fr) 1998-07-07 2001-09-21 Pf Medicament Formulations thixotropes pour le remplissage de gelules
AU8761498A (en) 1998-07-30 2000-02-21 Minnesota Mining And Manufacturing Company Nanosize metal oxide particles for producing transparent metal oxide colloids and ceramers
US6319513B1 (en) 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6258896B1 (en) 1998-12-18 2001-07-10 3M Innovative Properties Company Dendritic polymer dispersants for hydrophobic particles in water-based systems
EP1148905A2 (de) * 1999-02-03 2001-10-31 Max-Delbrück-Centrum Für Molekulare Medizin Druckluftinhalator zur pulmonalen applikation liposomalen pulver-aerosols sowie dafür geeignete pulver-aerosole
US6238798B1 (en) * 1999-02-22 2001-05-29 3M Innovative Properties Company Ceramer composition and composite comprising free radically curable fluorochemical component
ES2293913T3 (es) 1999-07-20 2008-04-01 THE PROCTER & GAMBLE COMPANY Particulas de aceite encapsulado mejoradas.
AU776770B2 (en) 1999-12-03 2004-09-23 Kuraray Co., Ltd. Dental or oralogic composition
WO2001085136A2 (en) 2000-05-10 2001-11-15 Alliance Pharmaceutical Corporation Phospholipid-based powders for drug delivery
FR2808704B1 (fr) 2000-05-10 2002-08-16 Rhodia Chimie Sa Agents tensioactifs formes par des particules minerales de dimension nanometrique de surface modifiee
CA2425035A1 (en) 2000-10-09 2002-04-18 3M Innovative Properties Company Medicinal aerosol formulations
US20040081627A1 (en) 2000-10-09 2004-04-29 Jinks Phillip A Medicinal aerosol formulations
US6467897B1 (en) 2001-01-08 2002-10-22 3M Innovative Properties Company Energy curable inks and other compositions incorporating surface modified, nanometer-sized particles
US6586483B2 (en) 2001-01-08 2003-07-01 3M Innovative Properties Company Foam including surface-modified nanoparticles
JP4293735B2 (ja) 2001-01-19 2009-07-08 三栄源エフ・エフ・アイ株式会社 フラーレン誘導体およびそれからなる組成物
FR2830450B1 (fr) 2001-10-09 2004-02-06 Univ Pasteur Utilisation de dendrimeres dans une composition ophtalmique
US7001580B2 (en) * 2002-12-31 2006-02-21 3M Innovative Properties Company Emulsions including surface-modified organic molecules
US7129277B2 (en) 2002-12-31 2006-10-31 3M Innovative Properties Company Emulsions including surface-modified inorganic nanoparticles
US7109247B2 (en) 2003-05-30 2006-09-19 3M Innovative Properties Company Stabilized particle dispersions containing nanoparticles
US7459146B2 (en) * 2003-05-30 2008-12-02 3M Innovative Properties Company Stabilized aerosol dispersions

Similar Documents

Publication Publication Date Title
JP2006526624A5 (ja)
Shur et al. The role of fines in the modification of the fluidization and dispersion mechanism within dry powder inhaler formulations
JP6087887B2 (ja) 吸入器
DK1732515T3 (da) Törpulverpræparater til fordoserede törpulverinhalatorer
JP2002538110A5 (ja)
JP2004503482A5 (ja)
WO2009112273A3 (en) Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
JP2003533470A5 (ja)
CA2797186A1 (en) Inhaler for delivering a metered dose
WO2001078693A3 (en) Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets
KR20150031315A (ko) 건조 분말 약물 전달 시스템 및 방법
CA2867097A1 (en) Method and apparatus
JP2014530231A5 (ja)
JP2014528470A5 (ja)
Rogueda et al. The nanoscale in pulmonary delivery. Part 2: formulation platforms
Yeung et al. Limitations of high dose carrier based formulations
MY157186A (en) Drug delivery system for administration of poorly water soluble pharmaceutically active substances
Hassoun et al. Formulating powder–device combinations for salmeterol xinafoate dry powder inhalers
JP2004532252A5 (ja)
Adi et al. Co-deposition of a triple therapy drug formulation for the treatment of chronic obstructive pulmonary disease using solution-based pressurised metered dose inhalers
Carr et al. Triamterene nephrolithiasis: renewed attention is warranted
MX2011005892A (es) Metodo y aparato para el empaque y dispensado de productos farmaceuticos.
Ali et al. A recent progresses and manufacturing techniques in pharmaceutical powders and granulation
Jämstorp et al. Influence of drug distribution and solubility on release from geopolymer pellets—A finite element method study
WO2006105367A3 (en) Magnetically-labeled microparticles for oral drug delivery